Provectus 生物製藥公司

StephenW

Provectus 生物製藥公司
2022 年 1 月 28 日星期五 12:00 AM·2 分鐘閱讀

田納西州諾克斯維爾，2022 年 1 月 27 日 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) 今天提供了其研究性免疫療法 PV-10（玫瑰孟加拉鈉，一種鹵化呫噸小分子）作為免疫佐劑的最新研究癌症和病毒疫苗，以提高疫苗接種後的免疫反應，同時公司不斷努力擴大其知識產權。

2022 年 1 月 20 日，美國專利商標局 (USPTO) 公佈了 Provectus 題為“作為疫苗佐劑的滷代呫噸”的專利申請（公開號 US 2022/0016242 A1），其中包括：

    體外數據顯示，對於代表乙型肝炎病毒 (HBV) 核心蛋白 (HBcAg) 的各種抗原區域的肽，PV-10 能夠顯著增加產生干擾素 (IFN) γ 的 CD8 細胞的數量（與對照相比）。選擇這些肽是因為它們能夠產生針對 HBV 的 CD4 和 CD8 T 細胞。

公司董事會副主席 Dominic Rodrigues 表示：“免疫佐劑可以幫助疫苗產生更快、更有效和持久的免疫反應。這項新研究進一步支持了 Provectus 小分子醫學科學平台的多方面免疫原性，這是我們開髮變革性、價格合理的免疫治療藥物工作的基礎。”

關於 Provectus

Provectus Biopharmaceuticals, Inc.（Provectus 或公司）是一家臨床階段的生物技術公司，基於稱為鹵化呫噸的小分子家族開發針對不同疾病領域的免疫治療藥物。多途徑給藥藥物發現和開發計劃包括腫瘤學（臨床階段）、皮膚病學（臨床階段）、血液學、病毒學、微生物學、眼科（臨床階段）和動物健康領域的研究藥物和藥物靶點。有關公司臨床試驗的信息可在美國國立衛生研究院 (NIH) 登記處 www.clinicaltrials.gov 找到。有關 Provectus 的更多信息，請訪問公司網站 www.provectusbio.com。

StephenW

Provectus Biopharmaceuticals Inc.
Fri, January 28, 2022, 12:00 AM·2 min read

KNOXVILLE, TN, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided an update on research of its investigational immunotherapy PV-10 (rose bengal sodium, a halogenated xanthene small molecule) as an immune adjuvant in vaccines for cancer and viruses to improve immune response upon vaccination, in conjunction with the Company’s ongoing efforts to expand its intellectual property.

On January 20, 2022, the U.S. Patent and Trademark Office (USPTO) published Provectus’ patent application entitled “Halogenated Xanthenes as Vaccine Adjuvants” (publication no. US 2022/0016242 A1), which contained among other things:

    In vitro data that showed PV-10 was able to significantly increase numbers of interferon (IFN) gamma-producing CD8 cells (compared to controls) for peptides representing various antigenic regions of the Hepatitis B virus (HBV) core protein (HBcAg). These peptides were selected for their capability to raise CD4 and CD8 T cells against HBV.

Dominic Rodrigues, Vice Chair of the Company’s Board of Directors, said, “Immune adjuvants can help vaccines generate quicker, more efficacious and durable immune responses. This new research further supports the multi-faceted immunogenicity of Provectus’ small molecule medical science platform, which is the foundation of our work to develop transformative, accessibly-priced immunotherapy medicines.”

About Provectus

Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on a family of small molecules called halogenated xanthenes. Multi-route of administration drug discovery and development programs include investigational drugs and drug targets in oncology (clinical-stage), dermatology (clinical-stage), hematology, virology, microbiology, ophthalmology (clinical-stage), and animal health. Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com.